Search Results
Results found for "Ethan Dintzner"
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
Intracellular Drugs” Now Only in Terry’s Corner Why Terry’s Corner In a world where GPCR science moves faster than
- Platelets in the NETworks interweaving inflammation and thrombosis
In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling
- Do You Believe AI Could Accelerate Drug Discovery?
Of 161 molecules tested, 42 substituted more than 50% of [³H]-LSD at 10 μM, achieving a 26% hit rate.
- Dynamic GPCR activation revealed through time-resolved Cryo-EM
of GPCR activation has always been a challenge because G protein activation in cells occurs in less than
- Unlocking the Therapeutic Potential of Previously Undruggable GPCRs
These receptors have much larger binding pockets than the majority of GPCRs that have been successfully ’ interaction ensures that all molecules in the library are specific for the target receptor rather than either G protein signaling or arrestin signaling, and superagonists with signaling activity higher than conjugate exhibited poor selectivity for CCR5-expressing cells and was less effective at killing cells than Orion’s CCR2 antagonist analog (OB-004), discovered in only 6 months, is considerably more potent than
- How Breakthroughs Happen: Eric Trinquet on Innovation, Serendipity & GPCRs
At early stages, breadth matters more than precision. Cast a wide net. Follow anomalies.
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
internalize both receptors whereas pasireotide promoted robust receptor internalization at shorter times than
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
The GPCR Precision Blueprint is more than a concept.
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
method can’t resolve subtle potency differences, the team prefers to acknowledge that limitation rather than
- The Five Traps of Ignoring Kinetics
That’s your signal: kinetics are moving faster than your tools can measure.
- Curve Shifts Don’t Lie, But Your Eyes Might
against standards and across methods Trust that your conclusions reflect reality, not bias This is more than
- Understanding the Journey: Catherine Demery's Path to Addiction Science
She found herself drawn toward the science behind the drugs, rather than their clinical application.
- TM5-TM6: structural switches that modulate the coupling of serotonin receptors to Gs or Gi
suggesting that the selectivity of the G-protein lies in intrinsic features of the receptor rather than
- Targeting GPCRs in the CNS: Advances in Drug Discovery Strategies
BBB , and since their targets are on the membrane of cells, they have easier access to the receptors than
- Why Opposing Processes Matter for Your Next GPCR Drug
example, invites reflex bradycardia that blunts its heart rate liability—making it a better inotrope than
- Beyond Clearance: The Strategic Power of Irreversible Drug Binding
When a compound’s off-rate is slower than its clearance, its biological effect outlives its plasma presence
- Biased Agonism at the GLP-1 Receptor: A Pathway to Improved Therapeutic Outcomes
Moreover, exendin-P5 has been observed to reduce adipose tissue size more effectively than exendin, suggesting
- From Snapshots to Predictions: Why Mechanism of Action Matters
mechanisms with confidence Apply models to design cost-efficient, informative experiments This is more than
- How Understanding Intracellular Drug Access Can Transform Your GPCR Drug Discovery Program
For drug discovery teams and scientists, staying ahead requires more than just reading papers—it demands
- Harnessing Deep Mutational Scanning for Enhanced Drug Discovery
role in disease pathology and highlight allosteric sites that might be more amenable to drug targeting than
- 📰 GPCR Weekly News, July 1 to 7, 2024
Submit your abstract today; you have less than two weeks!
- Chemokine receptor-targeted drug discovery: progress and challenges
overexpressed and promote cancer progression, and use promiscuous non-peptide antagonists able to target more than
- 📰 GPCR Weekly News, June 17 to 23, 2024
Epilepsy Models Biophysicists decipher functionality of adrenaline-binding receptor Tectonic plates more than
- Structural landscape of the Chemokine Receptor system
The chemokine system exhibits great versatility, with more than 50 chemokines interacting with over 20 Currently, there are more than 40 available structures of chemokines and their receptors in the Protein
- Odorant receptors – a bit of smell for drug discovery
is quite stable, the number of ORs expressed in different human tissues is highly variable from more than
- Overview of adhesion GPCRs self-activation
each G protein with the receptor showed that there are more polar interactions in Gq/Gs engagements than
- Feeder or trigger – CCR2 as a scavenger and regulator of cell migration
with CCR2, indicating that β-arrestin regulates scavenging and signaling of CCR1 to a greater extent than
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Rather than being static structures, GPCRs exist in an ensemble of different conformations that are interchangeable coupling was primarily attributed to differences in the conformational dynamics of the receptor rather than



















